Eurizon Capital SGR S.p.A. Acquires New Shares in Teva Pharmaceutical Industries Ltd. $TEVA

Eurizon Capital SGR S.p.A. acquired a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 26,001 shares of the company’s stock, valued at approximately $812,000.

Other large investors have also bought and sold shares of the company. Allworth Financial LP boosted its stake in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares in the last quarter. Grove Bank & Trust boosted its stake in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after buying an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares in the last quarter. Global Retirement Partners LLC boosted its stake in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares in the last quarter. Finally, 1620 Investment Advisors Inc. boosted its stake in Teva Pharmaceutical Industries by 1,823.2% in the fourth quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock valued at $49,000 after buying an additional 1,495 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $32.72 on Thursday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $37.62 billion, a price-to-earnings ratio of 24.60, a PEG ratio of 3.37 and a beta of 0.84. The business’s 50-day moving average price is $32.62 and its 200-day moving average price is $31.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The company had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Analyst Ratings Changes

TEVA has been the topic of a number of recent research reports. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Barclays lifted their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. UBS Group lifted their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Finally, Truist Financial lifted their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Insider Buying and Selling

In related news, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at approximately $1,973,727. This represents a 34.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 421,470 shares of company stock valued at $14,570,945 over the last 90 days. 0.54% of the stock is currently owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.